Search - tctmd.com

Displaying 301 - 320 of 525

Sort: Relevancy | Date

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

研究显示糖尿病患者急性心梗后风险差异很大

L.A. McKeown

May 26, 2016

News Daily News

Un Estudio Revela un Sorprendente Rango de Riesgo Post-IAM entre Pacientes con Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

Presentation

Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus

Presenter: Suzanne V. Arnold

May 25, 2016

News Daily News

尽管有指南说明，但糖尿病患者多支 CAD 患者接受 PCI 的人数仍多于 CABG

Yael L. Maxwell

May 13, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Yael L. Maxwell

May 13, 2016

News Daily News

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

Yael L. Maxwell

May 13, 2016

Presentation

Revascularization Trends in Pts with Diabetes and Multivessel CAD Presenting with NSTEMI

Presenter: Ambarish Pandey

May 12, 2016

News Industry News

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

May 06, 2016

News Daily News

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Michael O'Riordan

April 25, 2016

News Daily News

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Michael O'Riordan

April 25, 2016

News Daily News

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

Michael O'Riordan

April 25, 2016

Presentation

PCI in Patients With Insulin-Treated andNon-Insulin-Treated Diabetes Mellitus

Presenter: Sripal Bangalore

April 22, 2016

News Daily News

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

Michael O'Riordan

March 25, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Daily News

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Michael O'Riordan

March 25, 2016

News Industry News

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

March 06, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

糖尿病对 DES 治疗的患者的影响甚于病变复杂性

L.A. McKeown

February 03, 2016

Advertisement

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

研究显示糖尿病患者急性心梗后风险差异很大

Un Estudio Revela un Sorprendente Rango de Riesgo Post-IAM entre Pacientes con Diabetes

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus

尽管有指南说明，但糖尿病患者多支 CAD 患者接受 PCI 的人数仍多于 CABG

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

A Pesar de las Directrices, Más Diabéticos con EAC Multivaso son sometidos a PCI que a CABG

Revascularization Trends in Pts with Diabetes and Multivessel CAD Presenting with NSTEMI

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

PCI in Patients With Insulin-Treated andNon-Insulin-Treated Diabetes Mellitus

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

糖尿病对 DES 治疗的患者的影响甚于病变复杂性

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content